Proprio, Inc.

Based in the US, Proprio Vision, Inc. specializes in surgical technology, offering innovative software that enhances surgical precision and provides real-time data intelligence to improve patient outcomes during procedures. Proprio Vision, Inc. develops advanced surgical technology.

Founded in 2016, the company is headquartered in Seattle, US, and has primarily focused on modernizing surgical practices. The company has successfully completed 5 funding deals, with the latest being a Series B round on July 27, 2023, raising USD 43. 00 mn led by Sigma Group, alongside other investors including Bird B. AG and Wheelhouse Capital Partners.

The current valuation of Proprio Vision is USD 104. 09 mn. The company was co-founded by Gabriel Jones and Samuel Browd, with Jones serving as the CEO. Proprio is at the forefront of surgical technology, focusing on modernizing surgical practices through its proprietary platform that integrates light field technology, computer vision, and real-time data intelligence.

The core offerings enhance surgical precision and decision-making, ultimately improving patient outcomes. Designed for operating rooms, the technology provides critical insights for surgeons and OR staff, significantly impacting healthcare facilities in North America and Europe where demand for advanced surgical tools is increasing. Users include various medical professionals, especially those in complex and minimally invasive surgery. Proprio generates revenue through direct partnerships and licensing agreements with healthcare institutions and surgical facilities.

Its business model includes the sale of advanced technology systems and options for software subscriptions and ongoing support. While specific pricing is not disclosed, the offerings likely feature tiered pricing plans aligned with the scale of implementation and services provided. Proprio's products are integral to the surgical ecosystem, supporting data-driven decision-making in contemporary healthcare settings. In July 2023, Proprio Vision raised USD 43.

00 mn in Series B funding, aimed at accelerating product commercialization and expanding market reach. The company is focused on launching new products designed to enhance surgical practices and targeting expansion into additional geographical markets, particularly in North America and Europe, by 2024. This funding will facilitate the development and distribution of innovative surgical technologies.